TABLE 2.
Outcome in clinically documented infections in evaluable patients
| Type of infection | No. of patients (%) treated witha:
|
|||
|---|---|---|---|---|
| Meropenem
|
Cefuroxime-gentamicin (±metronidazole)
|
|||
| Total | Satisfactory outcome | Total | Satisfactory outcome | |
| Primary | ||||
| Urinary tract | 6 | 3 (50) | 5 | 3 (60) |
| Intra-abdominal | 7 | 4 (57) | 3 | 2 (67) |
| Pneumoniac | 20 | 17 (85) | 21 | 16 (76) |
| Sepsis syndrome alone | 3 | 2 (50) | 1 | |
| Sepsis syndrome with other | 1 | 2 | 2 (50) | |
| Otherd | 1 | 3e | ||
| Bacteriologically documented | 22 (60) | 19 (58) | ||
| Polymicrobial | 11 (30) | 7 (21) | ||
| Total | 37 | 26 (70) | 33 | 24 (73)b |
a
No significant difference in clinical outcome between the groups (P = 1.00; 95% CI, −24 to 19%).
b
One patient in the cefuroxime-gentamicin (metronidazole) group with another infection also improved.
c
No significant difference in clinical outcome between the groups (P = 1.00; 95% CI, −26 to 21%).
d
Some patients had more than one type of infection.
e
A patient with decubitus was treated with cefuroxime-gentamicin and metronidazole for 20 days.